Valeant forecast overshadows strong quarter
By The Associated Press - AP - Thu Jul 31, 12:04PM CDT
Shares of Valeant Pharmaceuticals plunged 7 percent Thursday after the company slashed its earnings and revenue forecasts.
Global Parkinson's Disease Market 2014-2018: Key Vendors are Boehringer Ingelheim, GlaxoSmithKline, Novartis and Teva
M2 - Thu Jul 31, 5:48AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l95k93/global) has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent leads to the development of symptoms associated with Parkinson's disease such as tremor, bradykinesia, and muscular rigidity. It is usually diagnosed in the population aged 60 and over; however, earlier incidences have been reported. Based on the severity, it can be categorized into early stage, mid stage and late (or advanced) stage. Currently, the approved therapies provide only symptomatic relief. Levodopa is the standard drug for the treatment of Parkinson's disease; however, it is associated with the incidence of dyskinesias. Alternative surgical procedures such as bilateral globus pallidus interna stimulation and bilateral subthalamic nucleus stimulation can be used in Parkinson's disease patients under certain circumstances. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation by MOA 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Late-Stage Pipeline Candidates 18. Other Prominent Vendors 19. Key Vendor Analysis 20. Other Reports in this Series Companies Mentioned: - Boehringer Ingelheim GmbH - GlaxoSmithKline plc - Novartis AG - Teva Pharmaceutical Industries Ltd. - Abbvie Inc. - Akorn Inc. - Astellas Pharma Inc. - Desitin Arzneimittel GmbH - Endo International plc - F. Hoffmann-La Roche Ltd. - H. Lundbeck A/S - Kyowa Hakko Kirin - Merck & Co. Inc. - Orion Corp. - STADA Arzneimittel AG - UCB Inc. - US WorldMeds LLC - Valeant Pharmaceuticals International Inc. For more information visit http://www.researchandmarkets.com/research/l95k93/global
Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results
PR Newswire - Thu Jul 31, 5:00AM CDT
-- 2014 Second Quarter Total Revenue $2.0 billion; an increase of 86% over the prior year
Global Retinal Vein Occlusion Market 2014-2018: Key Vendors are Bayer, F. Hoffmann-La Roche, Novartis and Regeneron Pharmaceuticals
M2 - Wed Jul 30, 5:40AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rqg93q/global_retinal) has announced the addition of the "Global Retinal Vein Occlusion Market 2014-2018" report to their offering. Retinal vein occlusion is a medical condition where there is a blockage in the retinal veins. This blocks the flow of blood in the retina, which can damage the nerve cells of the eye and result in loss of vision. Retinal vein occlusion can occur as a result of a clot in a vein, especially if the veins of the eye are very narrow. The disease is likely to affect people who are already suffering from hypertension, diabetes mellitus, or hyperlipidaemia. Retinal vein occlusion is one of the most common causes of blindness after diabetic retinopathy. It is also one of the most common vascular disorders of the eye. Retinal vein occlusion can be broadly classified into two types, central retinal vein occlusion and branch retinal vein occlusion, with the latter being more frequent. Central retinal vein occlusion can be divided into two further subtypes, ischemic central retinal vein occlusion and non-ischemic central retinal vein occlusion. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Pipeline Portfolio 08. Rate of Incidence and Prevalence 09. Market Segmentation by Type of Therapy 10. Market Segmentation by Route of Administration 11. Market Segmentation by Dosage Forms 12. Geographical Segmentation 13. Buying Criteria 14. Market Growth Drivers 15. Drivers and their Impact 16. Market Challenges 17. Impact of Drivers and Challenges 18. Market Trends 19. Trends and their Impact 20. Vendor Landscape 21. Key Vendor Analysis 22. Other Reports in this Series Companies Mentioned: - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Regeneron Pharmaceuticals Inc. - Alimera Sciences - Bristol-Myers Squibb - NicOx - Santen Pharmaceutical Co. - Valeant Pharmaceuticals International For more information visit http://www.researchandmarkets.com/research/rq...al_retinal
Aurinia Adds Financial Expertise to Its Board of Directors
GlobeNewswire - Tue Jul 29, 7:00AM CDT
Aurinia Pharmaceuticals Inc. ("Aurinia" or the "Company"
Valeant Pharmaceuticals Files An Official Complaint With The Autorite Des Marches Financiers About Allergan's False And Misleading Statements
CNW Group - Thu Jul 24, 7:00AM CDT
Valeant Pharmaceuticals International, Inc. ("Valeant"
Business Highlights
By The Associated Press - AP - Mon Jul 21, 5:03PM CDT
___
Allergan to cut 1,500 employees in restructuring
By TOM MURPHY - AP - Mon Jul 21, 4:14PM CDT
Botox maker Allergan will cut about 13 percent of its workforce as part of a push to become more efficient while it fights a hostile takeover bid from Valeant Pharmaceuticals.
Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements
CNW Group - Mon Jul 21, 6:13AM CDT
Valeant Pharmaceuticals International, Inc. ("Valeant"
Valeant awarded US FDA 510(k) approval for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery
M2 - Fri Jul 18, 9:36AM CDT
Specialist pharmaceutical company Valeant Pharmaceuticals International (NYSE:VRX)(TSX:VRX) reported on Thursday the receipt of 510(k) clearance in the US for the VICTUS Femtosecond Laser Platform for laser-assisted lens fragmentation during cataract surgery.
Valeant Pharmaceuticals Files Investor Presentation
PR Newswire - Fri Jul 18, 7:00AM CDT
Valeant Pharmaceuticals International, Inc. ("Valeant"
Health Care Sector Stocks Technical Review: Valeant Pharma, Teva Pharma Industries, Novo Nordisk, Curis, and Amarin
PR Newswire - Thu Jul 17, 7:10AM CDT
On Wednesday, July 16, 2014, the NASDAQ Composite ended at 4,425.97, up 0.22%, the Dow Jones Industrial Average finished the day 0.45% higher at 17,138.20, and the S&P 500 closed at 1,981.57, up 0.42%. The gains were broad based as seven out of ten sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 706.97, down 0.29%, while the index has advanced 2.56% in the last one month. Investor-Edge has initiated coverage on the following equities: Valeant Pharmaceuticals International Inc. (NYSE: VRX), Teva Pharmaceutical Industries Ltd (NYSE: TEVA), Novo Nordisk (NYSE: NVO), Curis Inc. (NASDAQ: CRIS), and Amarin Corp PLC (NASDAQ: AMRN). Free research on these five companies can be accessed at:
Bausch + Lomb's VICTUS® Femtosecond Laser Platform Receives 510(k) Clearance from FDA for Lens Fragmentation Procedure
PR Newswire - Thu Jul 17, 7:00AM CDT
Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that its wholly owned subsidiary, Bausch + Lomb has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the VICTUS® Femtosecond Laser Platform for laser-assisted lens fragmentation* during cataract surgery.
Scar Treatment Market to 2018: Gels, Creams, Oils and Sprays & Invasive Surgical Treatment, Laser Treatment, Elastic Wraps and Gel Sheets
M2 - Wed Jul 16, 8:44AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c4tlhl/global_scar) has announced the addition of the "Global Scar Treatment Market 2014-2018" report to their offering. Scar treatment products are applied on a scar to treat, heal, and conceal the scar. Products such as gels, creams, oils, and sprays are available as OTC products or are prescribed to treat scars. They are an alternative to invasive surgical treatment, laser treatment, elastic wraps, and gel sheets. Scar treatment application products are easy to use and cost-effective in comparison with invasive treatments. The Global Scar Treatment market can be divided into three segments: Burn Scars, Post-surgical Scars Other than Burn Scars, and Others. Burn scars, also known as hypertrophic scars, stay within the area of the original burn. The treatment of post-surgical scars varies with the degree of scarring. The treatment removes the scars caused by minor surgeries such as appendectomy or Caesarean section scars. Some scars can be hypersensitive and decrease ability to move. The Others segment includes scar treatment for aesthetic reasons such as the reduction in the appearance of acne scars. The Global Scar Treatment market is driven by many factors, one of which is an increase in appearance-consciousness among consumers. Scars leave an undesirable mark on the skin, which has a profound impact on the physical and mental well-being of a person. There has been an increase in the desire to maintain flawless skin, which is leading to an increase in the number of personal care and pharmaceutical scar treatment products. The report states that the risk of side effects is one of the major challenges. Scar treatment products may contain harmful chemicals that could cause side effects. Therefore, consumers are more concerned about the ingredients in these products. Some vendors are unable to meet the expectations of customers when it comes to safety standards. Key Vendors - CCA Industries Inc. - Merz Pharmaceuticals GmbH & Co. KGaA - Oculus Innovative Sciences Inc. - Pacific World Corp. Other Prominent Vendors - Avita Medical Ltd. - Enaltus LLC - Quantum Inc. - Revitol Corp. - Scarguard Labs LLC - Valeant Pharmaceuticals International Inc. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/c4...lobal_scar
Valeant Pharmaceuticals files HSR for planned acquisition of Allergan
M2 - Tue Jul 15, 8:39AM CDT
Valeant Pharmaceuticals International (NYSE:VRX)(TSX:VRX) said on Monday that it has filed a premerger notification under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) with the US Federal Trade Commission (FTC) with respect to the planned acquisition of Allergan (AGN).